HOME >> BIOLOGY >> NEWS
UC Davis breast cancer researchers report new insights into ductal carcinoma in situ

n their work in MIN, DCIS and invasive mammary cancer in mice.

Kermit L Carraway III, an associate professor of biochemistry and molecular medicine at UC Davis Cancer Center, reported his research into the role of a substance known as Nrdp1 in the path toward malignancy. Carraway's team discovered that when mouse and human breast cancer cells have excess Nrdp1, the levels of a growth factor known as ErbB3 drop, inhibiting the cancer cells' growth and motility. The same happens in mouse breast cancer cells with excess ErbB2. The growth factor ErbB2 is the mouse counterpart of the human growth factor HER2, which is implicated in a quarter of human breast cancers. The findings suggest Nrdp1 may have a role in the treatment of HER2-positive human breast cancers.

A second team reported that the seemingly inexorable progression of MIN cells towards mammary cancer could be halted in some cases. The team, led by Lawrence Young, a senior research associate in the Center for Comparative Medicine, and Jeff Gregg, an associate professor of pathology, found that the antibiotic rapamycin quickly induced apoptosis, or rapid cell death, in some but not all MIN cell lines. The researchers' next step will be to use micro-array genetic analysis to determine which genes were expressed in the surviving malignant cells. Such genes could be promising targets for drug development.

A third team presented work suggesting that diuretics may have therapeutic potential in DCIS. Steven Anderson, an associate researcher in physiology and membrane biology, and Peter Cala, professor and chair of physiology and membrane biology, have conducted specializing imaging studies to demonstrate that MIN cells rely on a molecule known as the sodium/hydrogen exchanger to maintain a favorable pH balance within the milk ducts. Diuretics inhibit sodium/hydrogen exchange, resulting in an acidic micro-environment that is lethal to cancer cells.

"This study has potential to p
'"/>

Contact: Claudia Morain
916-734-9023
University of California, Davis - Health System
6-Oct-2006


Page: 1 2 3

Related biology news :

1. UC Davis is partner in new $125 million federal bioenergy research center
2. UC Davis study finds high arsenic levels in herbal kelp supplements
3. UC Davis wins new national center for avian flu research
4. UC Davis researchers use heated nanoprobes to destroy breast cancer cells in mice
5. UC Davis researchers discover key to bodys ability to detect subtle temperature changes
6. APS names UC Davis professor Bodil Schmidt-Nielsen Distinguished Mentor and Scientist
7. UC Davis scientists groundbreaking research: Mate-attracting chemicals
8. British cattle give TB to badgers, finds UC Davis expert
9. UC Davis study finds distinct genetic profiles
10. UC Davis researchers move biotechnology closer to replacing electronic pacemakers
11. UC Davis study finds brain cell regulator is volume control, not on/off switch

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... Research and Markets has announced the addition of the "Biometric ... to their offering. ... The biometric vehicle access system market, in terms of value, ... to 2021. The market is estimated to be USD 442.7 Million ... The growth of the biometric vehicle access system market is fueled ...
(Date:12/15/2016)... Calif. , Dec. 15, 2016   WaferGen ... publicly held genomics technology company, announced today that on ... Listing Qualifications Department of The Nasdaq Stock Market LLC ... closing bid price of WaferGen,s common stock had been ... Accordingly, WaferGen has regained compliance with Listing Rule 5550(a)(2) ...
Breaking Biology News(10 mins):
(Date:1/12/2017)... ... January 12, 2017 , ... After her brain cancer ... gave her only a few months to live. Now a paper publishing January ... Rosendahl’s disease and increased both the quantity and quality of her life: Adding ...
(Date:1/12/2017)... and Pune, India , January 12, 2017 ... Market by Type and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," ... 2022 from $2,921 million in 2015, growing at a CAGR of 15.07% during the ... ... Allied Market Research Logo ...
(Date:1/11/2017)... ... January 11, 2017 , ... Phase 1 clinical trial ... of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The ... percent of these heavily pretreated patients saw clinical benefit from the drug, with ...
(Date:1/11/2017)... ... January 11, 2017 , ... Photonics industry and STEM ... are commending the U.S. Congress and President Obama for their recognition of the ... the American Innovation and Competitiveness Act (AICA). , The language of the act ...
Breaking Biology Technology:
Cached News: